Frontiers Launches Research Topic on Personalized Approaches in Gynecologic Oncology, Highlighting Precision Medicine and Rare Tumor Challenges
核心洞察
Frontiers in Oncology (搜索) announces a new Research Topic focused on case reports and clinical series of personalized approaches in gynecologic oncology, addressing evidence gaps in rare malignancies and molecularly defined subgroups.
The collection seeks to advance knowledge in precision oncology, including BRCA-associated tumors, homologous recombination deficiency, PARP inhibitor responses, and immunotherapy in rare histologies.
Surgical innovation themes include fertility-sparing procedures, ultra-radical cytoreductive surgery, robotic approaches, and sentinel lymph node mapping in complex clinical scenarios.
The rapidly evolving landscape of gynecologic oncology—marked by molecular stratification, targeted therapies, and increasingly complex surgical decision-making—has created a growing need for high-quality clinical documentation of rare and individualized cases. Frontiers in Oncology (搜索) has announced a new Research Topic, "Case Reports and Clinical Series of Personalized Approaches in Gynecologic Oncology," designed to capture precisely these experiences and bridge persistent evidence gaps.
Gynecologic malignancies represent a biologically heterogeneous group of cancers that remain a major cause of cancer-related morbidity and mortality among women worldwide. While large prospective trials and international collaborative studies have significantly advanced the management of common gynecologic cancers (搜索), a substantial proportion of clinically relevant scenarios remain insufficiently investigated because of their rarity, molecular complexity, or highly individualized presentation.
"In this context, carefully documented case reports and small case series retain a critical role in advancing scientific knowledge and improving patient care," the Research Topic editors note, emphasizing that clinicians are frequently confronted with uncommon clinical situations not adequately represented in conventional evidence-based guidelines.
Precision Oncology and Molecular Profiling Take Center Stage
The widespread implementation of next-generation sequencing and molecular tumor profiling has fundamentally transformed gynecologic oncology. Increasing identification of BRCA1/2 (搜索) mutations, homologous recombination deficiency (HRD), mismatch repair deficiency, POLE (搜索) mutations, HER2 (搜索) amplification, NTRK (搜索) fusions, and other actionable molecular alterations has generated new therapeutic opportunities, particularly in ovarian and endometrial cancers.
However, many molecularly defined subgroups remain rare, and their optimal management frequently derives from anecdotal experiences or small institutional cohorts. The Research Topic specifically invites submissions on exceptional responses to PARP inhibitors (搜索), immunotherapy in rare histologies, molecular tumor board experiences, and resistance mechanisms to targeted therapies.
Surgical Innovation in Complex and Uncommon Settings
Important advances in surgical oncology have expanded both the complexity and personalization of gynecologic cancer treatment. The collection welcomes contributions on fertility-sparing surgery in carefully selected patients, ultra-radical cytoreductive procedures, robotic and minimally invasive approaches, sentinel lymph node mapping in unusual contexts, and multidisciplinary pelvic exenteration.
"Unusual perioperative complications, innovative reconstructive strategies, and management of rare clinical scenarios are often best described through detailed case-based reports," the editors state, underscoring the unique value of institutional experiences and small series in contributing to clinical knowledge.
Hereditary Cancer Syndromes and Rare Tumors
The increasing integration of germline and somatic genetic testing into routine clinical practice has created new challenges regarding surveillance, preventive surgery, fertility preservation, and long-term survivorship. Patients carrying BRCA mutations, Lynch syndrome, RAD51C (搜索)/RAD51D (搜索), BRIP1 (搜索), PALB2 (搜索), and other moderate-penetrance mutations frequently present complex management dilemmas insufficiently addressed in large trials.
Rare gynecologic malignancies—including ovarian carcinosarcoma, mesonephric-like adenocarcinoma, neuroendocrine carcinomas, gestational trophoblastic neoplasia, sex cord-stromal tumors, and vulvovaginal melanomas—continue to suffer from profound evidence gaps due to their low incidence. These entities are rarely included in randomized studies, making collaborative publication of institutional experiences essential for improving understanding of disease biology, prognostic factors, and therapeutic approaches.
Translational and Technological Innovation
The Research Topic also recognizes the increasing relevance of artificial intelligence-assisted imaging, radiomics, liquid biopsy, molecular diagnostics, digital pathology, and integrated genomic analysis in clinical practice. Case-based reports describing successful or challenging applications of these technologies may help bridge the gap between translational research and real-world implementation.
Historically, several major oncologic advances—including novel therapeutic indications, unexpected drug toxicities, hereditary syndromes, and new pathologic entities—were initially recognized through individual clinical observations. In the current era of personalized oncology, this role may become even more important as increasingly fragmented molecular subgroups reduce the feasibility of traditional large-scale studies.
The collection aims to strengthen collaboration among gynecologic oncologists, pathologists, geneticists, translational researchers, radiologists, reproductive specialists, and allied healthcare professionals worldwide, ultimately contributing to a more individualized and evidence-informed approach to gynecologic cancer care.